Study Flags Arrhythmia Risk in Anthraquinone Cancer Drugs
Computational modeling points to possible heart-rhythm effects from seven antitumor drugs, pending laboratory and clinical validation.
Updated on Nov. 10, 2026 in Heart Disease

Researchers used network toxicology to model how seven anthraquinone-related antitumor drugs could trigger arrhythmias, screening 195 potential toxicity targets. The study, published in early form on November 10, 2026, suggests Mitoxantrone and Losoxantrone may block the cardiac hERG potassium channel.
Why it matters
Arrhythmia is a recognized cardiotoxic concern for chemotherapy agents, and computational screening can help prioritize which drugs warrant closer cardiac monitoring. The findings are predictive rather than confirmatory, so they point to hypotheses that require experimental testing.
The analysis relied on computational screening across 195 potential toxicity targets using STRING and Cytoscape 3.10.1, rather than patient or lab measurements. Whether the predicted hERG blockade translates to clinically meaningful arrhythmia risk has not been established.
The players
Mitoxantrone
Mitoxantrone is an anthraquinone-class antitumor drug that the study flagged as a possible hERG potassium channel blocker.
Losoxantrone
Losoxantrone is an anthraquinone-related antitumor drug that the study flagged as a possible QT-interval prolonger.
The details
The team built protein-protein interaction networks and screened candidate arrhythmogenic targets such as AKT1, SRC, TNF and TP53 using PubChem, Novo Pro and SwissTargetPrediction. Targets were enriched in PI3K-Akt and microRNA signaling pathways, and ADMET predictions flagged Mitoxantrone and Losoxantrone as possible QT-interval prolongers.
Timeline
• November 10, 2026: The study was published early as accepted peer-reviewed research.
Health Landscape
Drug-induced QT prolongation through hERG channel blockade is a long-established cardiac safety concern that regulators screen for during drug development. This computational study applies network toxicology to extend that screening logic to anthraquinone antitumor drugs.
The findings do not change current treatment for patients taking these drugs. Anyone on an anthraquinone-based chemotherapy with heart-rhythm concerns should discuss cardiac monitoring with their oncology or cardiology team.
The takeaway
Computational screening can flag possible cardiac risks early, but predicted effects require laboratory and clinical confirmation before changing patient care. Patients on these drugs should keep up with recommended heart monitoring.
Further reading
Explore more on Heart Disease to see how drug-related rhythm risks fit into cardiac care.
More information
Read the peer-reviewed study on anthraquinone drug arrhythmia mechanisms in Scientific Reports.
Source note: This article includes information reported by Nature.







